A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
PHASE1CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
February 28, 2001
Primary Completion Date
June 30, 2001
Study Completion Date
June 30, 2001
Conditions
Epilepsy
Interventions
DRUG
Placebo
DRUG
BIA 2-093
Trial Locations (1)
SE1 1YR
Guy's Drug Research Unit, London
All Listed Sponsors
lead
Bial - Portela C S.A.
INDUSTRY
NCT02171234 - A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093 | Biotech Hunter | Biotech Hunter